Last 47 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
Zevra Therapeutics, Inc.'s quarterly P/E stands at 3.9x.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 8.15 | 3.88 | 11.20 | — | 1.62 | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 6.11 | 3.87 | 3.76 | 5.10 | 4.79 | 4.97 | 9.29 | 22.45 | 11.54 | 17.69 | 4.70 | 14.45 | 5.10 |
| — | -22.0% | -59.5% | -77.3% | -58.5% | -71.9% | +97.9% | +55.3% | +126.1% | +18.5% | -72.5% | -22.8% | -82.7% | |
| P/B Ratio | 4.07 | 2.73 | 3.32 | 4.00 | 4.23 | 9.88 | 11.28 | 4.76 | 6.32 | 4.96 | 4.01 | 2.48 | 2.52 |
| — | -72.4% | -70.6% | -16.0% | -33.0% | +99.0% | +181.2% | +91.7% | +150.5% | +87.0% | +90.3% | +8.1% | +63.0% | |
| P/FCF | — | 22.98 | 23.12 | 32.02 | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | 2.24 | 13.28 | 29.79 | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | 8.79 | 125.79 | 1.62 | 2065.73 | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Zevra Therapeutics, Inc.'s operating margin was 144.0% in Q1 2026, up 116.7 pp QoQ and up 170.3 pp YoY. This marks the 4th consecutive quarter of margin expansion, signaling a sustained improvement in operating efficiency. The trailing four-quarter average of -21.8% lags the current quarter, suggesting the recent improvement is above-trend.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 84.5% | 94.8% | 95.5% | 94.0% | 52.2% | 93.4% | 88.7% | 37.7% | 19.7% | 4.7% | 78.9% | 95.0% | 92.0% |
| — | +1.5% | +7.8% | +149.6% | +165.0% | +1899.5% | +12.3% | -60.4% | -78.6% | -95.1% | -15.9% | -0.1% | -4.2% | |
| Operating Margin | -4.0% | 144.0% | 27.3% | 15.9% | -274.5% | -26.3% | -128.0% | -739.0% | -534.8% | -598.1% | -111.0% | -530.7% | -73.8% |
| — | +647.8% | +121.3% | +102.2% | +48.7% | +95.6% | -15.3% | -39.2% | -624.6% | -48.1% | +72.2% | -130.2% | +96.1% | |
| Net Margin | 78.2% | 104.6% | 35.6% | -2.1% | 288.7% | -15.2% | -296.8% | -899.2% | -447.9% | -485.3% | -114.6% | -358.1% | -30.4% |
| — | +788.7% | +112.0% | +99.8% | +164.5% | +96.9% | -158.8% | -151.1% | -1374.3% | -16.6% | +70.5% | -55.6% | +98.4% |
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 85.7% | 21.0% | 8.5% | -0.4% | 94.4% | -7.7% | -65.3% | -65.0% | -49.0% | -30.0% | -23.4% | -15.2% | -3.7% |
| — | +373.7% | +112.9% | +99.3% | +292.6% | +74.4% | -178.7% | -326.2% | -1232.6% | -66.5% | -119.4% | -122.5% | +83.1% | |
| ROA | 36.0% | 13.5% | 4.4% | -0.2% | 34.8% | -1.8% | -19.3% | -19.8% | -13.5% | -10.3% | -9.7% | -8.5% | -2.4% |
| — | +861.5% | +122.7% | +99.0% | +358.4% | +82.8% | -98.6% | -133.2% | -455.5% | +13.8% | -26.7% | -56.3% | +87.4% | |
| ROIC | -2.9% | 29.3% | 4.7% | 2.3% | -54.0% | -6.1% | -16.3% | -31.9% | -34.7% | -27.2% | -16.7% | -27.1% | -15.3% |
| — | +580.0% | +128.9% | +107.1% | -55.8% | +77.6% | +2.5% | -17.9% | -127.2% | -4.4% | +20.0% | -103.7% | +75.5% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
Zevra Therapeutics, Inc.'s Debt/EBITDA ratio is 0.0x, down from 6.5x last quarter — comfortably within a safe range. The current ratio has improved 61.7% YoY to 4.89x, strengthening the short-term liquidity position. Debt/Equity has declined for 6 consecutive quarters, reflecting a deleveraging trend.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.41 | 0.01 | 0.41 | 0.47 | 0.53 | 1.51 | 1.52 | 0.86 | 1.83 | 0.91 | 0.71 | 0.66 | 0.20 |
| — | -99.6% | -73.1% | -45.2% | -71.0% | +66.2% | +114.9% | +29.3% | +809.4% | +358.7% | +183.0% | +337.9% | +39.2% | |
| Debt / EBITDA | — | 0.02 | 6.53 | 13.83 | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 5.68 | 4.89 | 5.68 | 8.62 | 7.85 | 3.02 | 2.53 | 2.88 | 2.00 | 2.10 | 1.18 | 6.31 | 5.67 |
| — | +61.7% | +124.8% | +198.9% | +292.6% | +43.8% | +114.1% | -54.3% | -64.7% | -68.5% | -84.7% | -37.5% | -53.6% | |
| Quick Ratio | 5.63 | 4.84 | 5.63 | 8.57 | 7.81 | 2.93 | 2.47 | 2.88 | 2.00 | 2.10 | 1.18 | 6.31 | 5.67 |
| — | +65.3% | +128.3% | +197.1% | +290.6% | +39.3% | +109.2% | -54.3% | -64.7% | -68.5% | -84.7% | -37.5% | -53.6% | |
| Interest Coverage | 11.87 | 30.48 | 7.50 | 0.52 | 39.28 | 0.03 | -8.28 | -13.37 | -8.41 | -21.71 | -19.41 | -36.89 | -12.44 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 47 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorDCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare business quality, growth, and profitability against top sector peers.
Start ComparisonQuick answers to the most common questions about buying ZVRA stock.
Zevra Therapeutics, Inc.'s current P/E is 8.1x. The average P/E over the last 3 quarters is 5.6x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Zevra Therapeutics, Inc.'s current operating margin is -4.0%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Zevra Therapeutics, Inc.'s business trajectory between earnings reports.